Boehringer Ingelheim GmbH and Zealand Pharma A/S’s weight loss drug candidate, BI 456906, has met the primary endpoint in a Phase II obesity trial but peak sales expectations remain low relative to first-in-class products from Novo Nordisk A/S and Eli Lilly and Company.
Boehringer/Zealand’s Obesity Asset Succeeds In Phase II But Competition Is Fierce
Pivotal Plans In The Works
The partners’ dual GLP-1/GCGR agonist has achieved up to 14.9% weight loss in obese and overweight adults in a mid-stage trial but rival products Wegovy and Mounjaro will likely dominate the space according to analysts.
